Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease

NCT05543681 is registered in ClinicalTrials.gov with IGC Pharma, LLC as lead sponsor.

NCT NCT05543681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05543681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants With Dementia Due to Alzheimer's Disease
Lead sponsor
IGC Pharma, LLC
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 11, 2022
Completion date
November 30, 2026
Enrollment
164 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

aggression, agitation,psychomotor, alzheimer disease, care giving burden, nps